@article{HeinsenHennEisenmengeretal.1994,
  author    = {Heinsen, Helmut and Henn, R. and Eisenmenger, W. and G{\"o}tz, M. and Bohl, J. and Bethke, B. and Lockermann, U. and P{\"u}schel, K.},
  title     = {Quantitative investigations on the human entorhinal area: left - right asymmetry and age-related changes},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-59946},
  year      = {1994},
  abstract  = {The total nerve cell numbers in the right and in the left human entorhinal areas have been calculated by volume estimations with the Cavalieri principle and by cell density determinations with the optical disector. Thick gallocyanin-stained serial frozen sections through the parahippocampal gyrus of 22 human subjects (10 female, 12 male) ranging from 18 to 86 years were analysed. The laminar composition of gallocyanin (Nissl)-stained sections could easily be compared with Braak's (1972, 1980) pigmentoarchitectonic study, and Braak's nomenclature of the entorhinal laminas was adopted. Cellsparse laminae dissecantes can more clearly be distinguished in Nissl than in aldehydefuchsin preparations. These cell-poor dissecantes, lamina dissecans extema (dis-ext), lamina dissecans 1 (dis-1) and lamina dissecans 2 (dis-2), were excluded from nerve cell nurober determinations. An exact delineation of the entorhinal area is indispensable for any kind of quantitative investigation. We have defined the entorhinal area by the presence of pre-alpha ceil clusters and the deeper layers of lamina principalis externa (pre-beta and gamma) separated from lamina principalis interna (pri) by lamina dissecans 1 (dis-1). The human entorhinal area is quantitatively characterized by a left-sided (asymmetric) higher pre-alpha cell number and an age-related nerve cell loss in pre as well as pri layers. At variance with other CNS cortical and subcortical structures, the neuronal number of the entorhinal area appears to decrease continuously from the earliest stages analysed, although a secular trend has to be considered. The asymmetry in pre-alpha cell number is discussed in the context of higher human mental capabilities, especially language.},
  subject      = {Medizin},
  language  = {en}
}
@article{VortkampThiasGessleretal.1991,
  author    = {Vortkamp, A. and Thias, U. and Gessler, Manfred and Rosenkranz, W. and Kroisel, P. M. and Tommerup, N. and Kruger, G. and Gotz, J. and Pelz, L. and Grzeschik, Karl-Heinz},
  title     = {A somatic cell hybrid panel and DNA probes for physical mapping of human chromosome 7p},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-59217},
  year      = {1991},
  abstract  = {No abstract available},
  subject      = {Biochemie},
  language  = {en}
}
@article{BrunekreeftStrohmGoodenetal.2014,
  author    = {Brunekreeft, Kim L. and Strohm, Corinna and Gooden, Marloes J. and Rybczynska, Anna A. and Nijman, Hans W. and Grigoleit, G{\"o}tz U. and Helfrich, Wijnand and Bremer, Edwin and Siegmund, Daniela and Wajant, Harald and de Bruyn, Marco},
  title     = {Targeted delivery of CD40L promotes restricted activation of antigen-presenting cells and induction of cancer cell death},
  series = {Molecular Cancer},
  volume    = {13},
  journal   = {Molecular Cancer},
  number    = {85},
  issn      = {1476-4598},
  doi       = {10.1186/1476-4598-13-85},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-116682},
  year      = {2014},
  abstract  = {Background: Stimulation of CD40 can augment anti-cancer T cell immune responses by triggering effective activation and maturation of antigen-presenting cells (APCs). Although CD40 agonists have clinical activity in humans, the associated systemic activation of the immune system triggers dose-limiting side-effects. Methods: To increase the tumor selectivity of CD40 agonist-based therapies, we developed an approach in which soluble trimeric CD40L (sCD40L) is genetically fused to tumor targeting antibody fragments, yielding scFv: CD40L fusion proteins. We hypothesized that scFv: CD40L fusion proteins would have reduced CD40 agonist activity similar to sCD40L but will be converted to a highly agonistic membrane CD40L-like form of CD40L upon anchoring to cell surface exposed antigen via the scFv domain. Results: Targeted delivery of CD40L to the carcinoma marker EpCAM on carcinoma cells induced dose-dependent paracrine maturation of DCs similar to 20-fold more effective than a non-targeted control scFv: CD40L fusion protein. Similarly, targeted delivery of CD40L to the B cell leukemia marker CD20 induced effective paracrine maturation of DCs. Of note, the CD20-selective delivery of CD40L also triggered loss of cell viability in certain B cell leukemic cell lines as a result of CD20-induced apoptosis. Conclusions: Targeted delivery of CD40L to cancer cells is a promising strategy that may help to trigger cancer-localized activation of CD40 and can be modified to exert additional anti-cancer activity via the targeting domain.},
  language  = {en}
}